Abstract. Breast carcinogenesis results from the accumulation of numerous somatic genetic alterations. although mutations of the tumor suppressor gene p53 are among the most common alterations identified in invasive breast carcinomas, it is not clear whether its alteration occurs frequently in non-invasive breast lesions, including usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). p53 mutations were examined in 140 cases of non-invasive breast lesions, including UDH, ADH and DCIS, by high-resolution melting (HRM), followed by DNA sequence analysis. Two hundred and forty cases of non-invasive breast lesions were subjected to the immunohistochemical staining of p53 protein. The HRM and sequencing analysis demonstrated that the positive rates of p53 mutation were 0.0, 12.7 and 21.6% in UDH, ADH and DCIS, respectively. p53 protein expression was detected in none of the UDH, 14.6% of the ADH and 31.4% of the DCIS samples. Statistically, p53 mutation and protein accumulation gradually increased from UDH to ADH and to DCIS (P<0.05). There was a significantly positive association between p53 mutations and expression in these samples. p53 mutations and accumulation occur in non-invasive breast lesions, including ADH and DCIS, and may represent early events in breast carcinogenesis.
Introduction
The p53 tumor suppressor gene is thought to play a central role in protecting against the development of cancer. As a transcription factor, its encoding protein is a master switch that coordinates and concentrates a plethora of stress signals and transforms them into a series of responses, such as apoptosis or cell cycle arrest in response to DNA damage, thereby maintaining genetic stability in the organism (1) . Mutations in p53 inactivating its function are frequently found in both familial and sporadic human cancers. More than 50% of human cancers harbor mutations in p53, and the p53 pathway is otherwise inactivated in most of the remaining cancers. In animal models, loss or mutation of p53 leads to a predisposition to a range of spontaneous and induced tumors, highlighting its protective role as a barrier to tumor development (2) . Although p53 inactivation in human cancer is a complex process, depending on the tissue type, p53 dysfunction may disorder the biological events of cancer cells and give rise to their aggressive phenotypes, poor patient survival and resistance to treatment (2) (3) (4) (5) (6) . The molecular genetic profile of p53 alterations has been well characterized in invasive breast cancer (6) (7) (8) . However, only a few studies have investigated p53 alterations in non-invasive breast lesions, including usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). Moreover, the findings of these studies differed significantly, in particular in the case of ADH.
At present, there are several long-standing methods available for the detection of mutations in oncogenes and tumor suppressor genes, including direct sequencing and singlestrand conformation polymorphism (SSCP) of PCR, both of which are time-consuming procedures and require skill to interpret the results (9) . High resolution melting (HRM) is a novel simple homogeneous close-tube and post-PCR method that enables genomic researchers to analyze genetic variations (SNPs, mutations and methylations) in PCR amplicons, particularly when only tiny samples are available (10) (11) (12) (13) (14) (15) . In HRM-designated instruments, the decrease in fluorescence caused by the transition of dsDNA to ssDNA with an increase in temperature is carefully monitored. With the aid of tailor-made analysis software, different genetic variants are discriminated by their characteristic melting curves. When melted in the presence of a saturating intercalating fluorescent dye, such as LCGreen I or Styo 9, and with the acquisition of fluorescence data over small temperature increments, amplicons containing different sequences are discriminated according to the melting transition of the Pcr product and the resulting melt curve shape. Certain studies have validated the use of HRM as a method for scanning somatic mutations in p53. It is sensitive, rapid and cost effective, and markedly reduces the amount of sequencing required in the mutational study of p53, and thereby the cost of these studies (16) (17) (18) (19) .
Worldwide, breast cancer comprises 10.4% of all incidences of cancer among women, making it the second most common type of non-skin cancer (after lung cancer) and the fifth most common cause of cancer-related death (20) . epithelial proliferation of the breast encompasses a variety of proliferative and pre-cancerous lesions, which have to potential to progress to carcinoma. Those formed in the terminal of the ductal units are categorized as UDH, ADH and DCIS (21) . To clarify genetic alterations in breast carcinogenesis, we aimed to investigate p53 mutations and its expression in a large number of non-invasive breast lesions, including UDH, ADH and DCIS samples, using HRM and immunohistochemistry. HRM assay. for each case, two H&e-stained slides of fresh frozen samples were used as guides to verify and locate the ADH and DCIS lesions. Genomic DNA was extracted from 140 cases among the 240 fresh frozen tissue samples by the phenol-chloroform method. Pcr primers were designed for the flanking site of exons 5, 6, 7 and 8 of the p53 gene (Table I) and synthesized by Sangon Ltd. (Shanghai, China). The DNA samples were further diluted to a concentration of 10 ng/µl for PCR. The PCR reaction mixture (20 µl) contained 10 ng genomic DNA, 1.5 mM MgCl 2 and 1X lightcycler ® 480 High Resolution Master Mix (Roche Diagnostics, Mannheim, Germany). Duplicate PCRs and the HRM analysis were conducted on a lightcycler ® 480 PCR system (Roche Diagnostics). The PCR profile was: an initial hold at 95˚C for 15 min, followed by 45 cycles of denaturation at 95˚C for 10 sec, annealing at 60˚C for 10 sec and extension at 72˚C for 25 sec. After the latter run, the sample was held at 95˚C for 1 min, at 40˚C for 1 min and then at 65˚C for 1 sec. This was followed by a melt step of 65-95˚C in 1˚C increments, pausing for 1 sec per step to generate the melt curve. Roche LightCycler ® 480 software (ver 1.5) was used to calculate the melt peaks by plotting the negative first derivative of the primary melt curve (fluorescence vs. temperature).
Materials and methods

Subjects
Sequence analysis of HRM products. Samples with the p53 variant-scanning panels whose melting profile deviated from that of the controls (both first-pass analysis and co-amplification) were recovered from the melt profiling plate for DNA sequence analysis, purified from gel using the QIAquick gel purification kit (Qiagen), and then subjected to automated sequencing (BigDye Terminator version 3.1; Applied Biosystems) in both directions using the PCR primers. Sequences were analyzed using Mutation Surveyor 3.1 software (SoftGenetics, State College, PA, USA).
Immunohistochemistry. for immunohistochemical analysis, 4-µm-thick sections of 240 formalin-fixed, paraffin-embedded specimens were deparaffinized with xylene and rehydrated through an alcohol gradient. immunohistochemical staining was performed with the streptavidin peroxidase system (Ultrasensitive™; Maixin-Bio, P.R. China) according to the manufacturer's instructions with a primary p53 specific antibody (Do-7, dilution 1:100; Santa Cruz Biotechnology, USA). for the negative control, sections were treated with 0.01 mol/l phosphate-buffered saline instead of the primary antibody. A slide was considered negative or positive according to the absence or presence of positive staining: no staining or <10% of total cells positive for p53 was considered negative; ≥10% of total cells positive for p53 was considered positive staining.
Statistical analysis.
Differences between the positive rates were evaluated using fisher's exact test. Analyses were performed using SPSS 13.0 statistical software for Windows. A P-value of <0.05 was considered statistically significant.
Results
A clear definition of the presence of somatic mutations in a sample was achievable by the comparison of the profile with wild-type dna. Sequencing analysis was performed in all samples using the same Pcr products after melting analysis. figs. 1 and 2 display the results of HRM and sequencing analysis. examples of HRM and melting profiles obtained from ADH and DCIS carried somatic mutations of exons 5-8 of p53 (Table II) . We found no mutations in 40 cases of UDH, one mutation in 8 (12.7%) of 63 cases of ADH, and at least one mutation in 8 (21.6%) of 37 cases of DCIS, with one of the cases harboring two mutations simultaneously. frequent p53 mutations were found in DCIS compared to ADH (P<0.05, Table III In 140 cases of non-invasive breast lesions, 10.7% (15/140) had both p53 expression and mutations, 84.3% (118/140) had neither mutations nor expression, 4.3% (6/140) had expression without mutations, and 1 had a p53 mutation without its expression. p53 expression was closely linked to p53 mutations (Table IV) .
Discussion
Mutations of p53 during carcinogenesis may lead to an increased stability of the originally unstable p53 proteins, and p53 protein accumulation has been interpreted as a result of p53 mutation in several studies (1-5,23 ). Many early investigators have found a 95% rate of p53 mutation in exons 5-8, which is highly conserved through evolution, and presumably of functional importance. Although p53 mutations and protein expression have frequently been observed in invasive breast cancer and are implicated in its development, only a few studies have reported alterations of p53 in pre-invasive breast lesions (24) (25) (26) (27) . The results of these studies differed significantly, particularly in the case of ADH. Done et al (24, 25) found that approximately 10% of DCIS carried a p53 missense mutation, and no mutations were identified in microdissected foci of epithelial hyperplasia, including one sample with atypia, suggesting that p53 mutations usually occur before the invasion of breast carcinomas. It should be noted that the authors only examined one sample of epithelial hyperplasia with atypia in their study. Keohavong et al (26) combined tissue microdissection and SSCP to investigate p53 mutations in paraffin-embedded breast tissue sections, including 6 cases of DCIS and 10 of ADH. p53 mutations were detected in 3 cases of DCIS and in 5 cases of ADH, indicating that p53 is genetically altered not only in DCIS, but also in ADH. However, data remain scarce, and it is necessary to further investigate p53 mutations and expression in non-invasive breast ADH and DCIS using a large sample, including a number of non-invasive breast lesions. HRM has high sensitivity and specificity, with a performance as good as, if not better than, other commonly used mutation scanning techniques (28) . It is a closed tube system that not only reduces the potential for contamination, but also increases sample throughput, as it is not necessary to physically separate the DNA molecules. HRM furthermore offers significant savings in cost and turnaround time, and is an attractive choice for p53 mutation scanning, especially in high-throughput environments. Sonia et al (16) undertook mutation screening of the entire p53 locus by HRM and direct sequencing using a set of 47 samples, and found the sensitivity and specificity of HRM for sequence variant detection to be 1.0 and 0.83. These results suggest that HRM provides sensitive assays for the detection of new sequence variants and the genotyping of known polymorphisms.
Here, we examined mutations of p53 exons 5-8 by HRM, and found its mutations in 16 samples. Sequence analysis indicated that 1 case was a nonsense mutation and 15 cases were missense mutations. p53 gene mutations occurred in 12.7% of the ADH samples and 21.6% of DCIS, but did not occur in UDH. Immunohistochemically, p53 protein was not expressed in UDH, but was observed in 14.6% of ADH and 31.4% of DCIS samples. cases with a nonsense p53 mutation had no p53 expression. p53 expression was closely linked to p53 mutations in non-invasive breast lesions, in agreement with the interpretation of mutant p53 protein accumulation as a result of its mutation. Additionally, there was a gradual increase in the incidence of p53 mutations and its expression from UDH to ADH and to DCIS, supporting the hypothesis that p53 mutations and subsequent accumulation may be involved in the tumorigenesis of breast tissue as an early event in ADH. The low frequency of p53 mutations in ADH compared to DCIS also supports the epidemiological evidence that these lesions have distinct differences, and may in part explain the different relative risks of invasive carcinoma. In summary, p53 mutations and consequent protein accumulation may be involved in breast tumorigenesis. It may be useful to monitor genetic alterations and aberrant p53 expression in pre-cancerous lesions of the breast. +  -+  15  1  16  -6  128  124  Total  21  119  140 
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